2025
Consensus Guideline for the Management of Gastric Cancer with Synchronous Peritoneal Metastases
Butensky S, Bansal V, Su D, Waheed M, Nikiforchin A, Gomez-Mayorga J, Olecki E, Radomski S, Sun B, Turaga K, Gunderson C, Lacy J, Badgwell B, In H, Kennedy T, Yoon H, Greer J, Sundar R, Woo Y. Consensus Guideline for the Management of Gastric Cancer with Synchronous Peritoneal Metastases. Annals Of Surgical Oncology 2025, 1-18. PMID: 40560499, DOI: 10.1245/s10434-025-17361-2.Peer-Reviewed Original ResearchSynchronous peritoneal metastasesCytoreductive surgeryPeritoneal metastasisConsensus guidelinesLow peritoneal carcinomatosis indexPeritoneal carcinomatosis indexManagement of gastric cancerMultidisciplinary preoperative assessmentLimited treatment optionsNon-surgical managementLevel of evidenceClinical management pathwaysDiagnostic laparoscopyRandomized Controlled TrialsSystemic therapySurvival benefitPreoperative assessmentDisease subsetsTreatment optionsClinical trialsGastric cancerPathway blockBurden of diseasePatientsBackgroundGastric cancerConsensus guideline for the management of gastric cancer with synchronous peritoneal metastases
Butensky S, Bansal V, Su D, Waheed M, Nikiforchin A, Gomez‐Mayorga J, Olecki E, Radomski S, Sun B, Turaga K, Gunderson C, Lacy J, Badgwell B, In H, Kennedy T, Yoon H, Greer J, Sundar R, Woo Y, Group P. Consensus guideline for the management of gastric cancer with synchronous peritoneal metastases. Cancer 2025, 131: e35870. PMID: 40558029, DOI: 10.1002/cncr.35870.Peer-Reviewed Original ResearchConceptsSynchronous peritoneal metastasesManagement of gastric cancerPeritoneal metastasisGastric cancerCytoreductive surgeryConsensus guidelinesLow peritoneal carcinomatosis indexPeritoneal carcinomatosis indexMultidisciplinary preoperative assessmentLimited treatment optionsPatient's goals of careLevel of evidenceGoals of careClinical management pathwaysCytology-negativeCytology-positiveRandomized Controlled TrialsDiagnostic laparoscopySystemic therapySurvival benefitBurden of diseasePreoperative assessmentNonsurgical managementDisease subsetsTreatment optionsEndothelial CLEC5A drives barrier dysfunction and vascular leakage responsible for lung injury in bacterial pneumonia and sepsis
Zhang T, Huang X, Goodwin J, Wen R, Liu Y, Yang Y, Zhang T, Zheng Y, Chen A, Hao P, Tong X, Yang N, Liu C. Endothelial CLEC5A drives barrier dysfunction and vascular leakage responsible for lung injury in bacterial pneumonia and sepsis. Science Advances 2025, 11: eadt7589. PMID: 40498836, PMCID: PMC12154197, DOI: 10.1126/sciadv.adt7589.Peer-Reviewed Original ResearchConceptsVascular leakagePuncture (CLP)-induced polymicrobial sepsisRegulating endothelial barrier functionCLP-challenged miceEndothelial barrier dysfunctionTrans-endothelial electrical resistanceEndothelial barrier functionLipopolysaccharide (LPS)-induced endotoxemiaVascular endothelial cellsPattern recognition receptorsSurvival benefitMultiorgan failurePolymicrobial sepsisTrans-endothelial migrationCecal ligationBacterial pneumoniaLung injuryBarrier dysfunctionVascular injurySingle-cell RNA sequencingDecreased mortalityInflammatory stormBacterial infectionsHeterogeneity of vascular endothelial cellsSepsisComprehensive molecular and immune characterization of adrenergic stress-signaling receptor ADRB2 in triple negative breast cancer (TNBC).
Deshmukh S, Wu S, Xiu J, Hong C, Yao S, Sudmeier L, Kalinski P, Chalasani P, Repasky E, Ernstoff M, Leone J, Chumsri S, Graff S, Lustberg M, Sledge G, Kalinsky K, Gandhi S. Comprehensive molecular and immune characterization of adrenergic stress-signaling receptor ADRB2 in triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2025, 43: 1107-1107. DOI: 10.1200/jco.2025.43.16_suppl.1107.Peer-Reviewed Original ResearchTriple negative breast cancerBreast cancerOverall survivalTumor microenvironmentReal-world overall survivalADRB2 gene expressionNegative breast cancerImmune cell fractionsB2 adrenergic receptorPromote tumor growthMann-Whitney U testHighest survival benefitTriple negative breast cancer samplesKaplan-Meier estimatesSurvival benefitImmunological featuresGene expressionPreclinical modelsImmune characterizationTumor growthMann-WhitneyObservational studyU testADRB2RNA expressionImpact of static and dynamic risk assessment in HMA-treated MDS patients undergoing stem cell transplantation.
Aguirre L, Kim H, Elmariah H, Frumm S, Kelkar A, Ho V, Gooptu M, Antin J, Soiffer R, Shimony S, Luskin M, Garcia J, Chen E, Winer E, Stone R, DeAngelo D, Al Ali N, Cutler C, Komrokji R, Stahl M. Impact of static and dynamic risk assessment in HMA-treated MDS patients undergoing stem cell transplantation. Journal Of Clinical Oncology 2025, 43: 6568-6568. DOI: 10.1200/jco.2025.43.16_suppl.6568.Peer-Reviewed Original ResearchIPSS-MHypomethylating agentsStem cell transplantationPre-HSCTCell transplantationPost-hematopoietic stem cell transplantationResponse to HMATreated with hypomethylating agentsIPSS-R scorePost-HSCT outcomesProgression-free survivalHigh-risk diseaseCytoreductive therapyMUD donorsIPSS-RMDS patientsIncreased blastsSurvival benefitNo significant differencePre-HCTPrognostic accuracyDana-FarberHSCTPrimary outcomeResponse evaluationTolerance for chemotherapy-induced peripheral neuropathy among women with metastatic breast cancer: a discrete-choice experiment
Radwan R, Schuster A, Hertz D, Lustberg M, Vachhani H, Hickey Zacholski E, Sheppard V, Bridges J, Salgado T. Tolerance for chemotherapy-induced peripheral neuropathy among women with metastatic breast cancer: a discrete-choice experiment. Breast Cancer Research And Treatment 2025, 212: 149-159. PMID: 40358649, PMCID: PMC12086117, DOI: 10.1007/s10549-025-07715-5.Peer-Reviewed Original ResearchConceptsDiscrete-choice experimentProgression-free survivalMetastatic breast cancerChemotherapy-induced peripheral neuropathyMonths of progression-free survivalDuration of progression-free survivalSevere chemotherapy-induced peripheral neuropathyLogit modelHousehold incomePreferencesPeripheral neuropathyBreast cancerNeuropathy severityNon-white womenWhite womenAggregationExploratory stratified analysesPFS benefitIncomeSurvival benefitHouseholdsNeurotoxic chemotherapyNeuropathyNon-whitePersistenceImetelstat in myeloid malignancies: current data and future directions
Bidikian A, Bewersdorf J, Kewan T, Podoltsev N, Stahl M, Zeidan A. Imetelstat in myeloid malignancies: current data and future directions. Expert Review Of Anticancer Therapy 2025, 25: 517-528. PMID: 40116730, DOI: 10.1080/14737140.2025.2482721.Peer-Reviewed Original ResearchMyelodysplastic syndromeLR-MDSClinical trialsPotential disease-modifying propertiesLow-risk myelodysplastic syndromesElevated liver enzymesLR-MDS patientsTreat myelodysplastic syndromeSearch of PubMedTransfusion independenceEssential thrombocythemiaInfusion reactionsMyeloid malignanciesDisease-modifying propertiesCombination therapySurvival benefitEffective telomerase inhibitorImetelstatTelomerase reactivationPatient populationLiver enzymesMyelofibrosisCancer cellsMalignancyConference abstractsCharacterization of Exceptional Responses in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Cabozantinib and Immune Checkpoint Inhibitors
Ganta T, Anker J, Miller E, Joshi H, Tsao C, Oh W. Characterization of Exceptional Responses in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Cabozantinib and Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer 2025, 23: 102336. PMID: 40222171, DOI: 10.1016/j.clgc.2025.102336.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerImmune checkpoint inhibitorsProstate cancerCheckpoint inhibitorsHigh tumor mutational burdenLack of survival benefitProgression-free survivalTumor mutational burdenPopulation of patientsCastration-resistantRetrospective seriesMutational burdenSurvival benefitTreatment selectionCabozantinibPatientsCancerRegulatory approvalExceptional responseRegimenLong-term responseSubpopulationsInhibitorsTherapyFirst-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.
Shen L, Bai Y, Lin X, Li W, Wang J, Zhang X, Pan H, Bai C, Bai L, Cheng Y, Zhang J, Zhong H, Ba Y, Hu W, Xu R, Guo W, Qin S, Hu N, McCraith S, Liu T. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649. Journal Of Clinical Oncology 2025, 43: 392-392. DOI: 10.1200/jco.2025.43.4_suppl.392.Peer-Reviewed Original ResearchBlinded independent central reviewObjective response rateProgression-free survivalCombined positive scorePD-L1CheckMate 649Overall survivalFollow-upSurvival benefitPD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Long-term survival benefitStudy populationDual primary endpointsDeath-ligand 1Gastroesophageal junction cancerDuration of responseAdvanced gastric cancerIndependent central reviewOS ratesJunction cancerCentral reviewPrimary endpointFirst-lineGermline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline
Yu E, Rumble R, Agarwal N, Cheng H, Eggener S, Bitting R, Beltran H, Giri V, Spratt D, Mahal B, Lu K, Crispino T, Trabulsi E. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. Journal Of Clinical Oncology 2025, 43: 748-758. PMID: 39787437, DOI: 10.1200/jco-24-02608.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerSomatic genomic testingProstate cancerMetastatic castration-resistant prostate cancerClinical trialsCastration-resistant prostate cancerGenomic testingPoly(ADP-ribose) polymerase inhibitorsSystematic reviewMetastatic biopsiesSurvival benefitASCO guidelinesPrognostic informationClinical statusGermline testingPolymerase inhibitorsPatientsScreening implicationsPubMed databaseCancerMultidisciplinary panelEligibility criteriaGermlineLiterature searchSequencing findings
2024
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS
Norman M, Yamartino K, Gerstein R, Shallis R, Mendez L, Podoltsev N, Stahl M, Eighmy W, Zeidan A. A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS. Expert Review Of Hematology 2024, 17: 755-767. PMID: 39474840, DOI: 10.1080/17474086.2024.2422554.Peer-Reviewed Original ResearchDiagnosed AMLSurvival benefitManagement of acute myeloid leukemiaDevelopment of oral therapiesIsocitrate dehydrogenase inhibitorsNewly diagnosed AMLManagement of adult patientsPost-transplant maintenanceAcute myeloid leukemiaSingle-arm studyExcellent response ratesIDH inhibitorsRelapsed AMLHypomethylating agentsInhibitor therapyMyelodysplastic syndromeOral therapyCombination therapyPost-transplantMyeloid leukemiaImproved survivalSingle-armAdult patientsAzacitidineRandomized studyTargeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival Benefit
Kume K, Iida M, Iwaya T, Yashima-Abo A, Koizumi Y, Endo A, Wade K, Hiraki H, Calvert V, Wulfkuhle J, Espina V, Siwak D, Lu Y, Takemoto K, Suzuki Y, Sasaki Y, Tokino T, Petricoin E, Liotta L, Mills G, Nishizuka S. Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival Benefit. Molecular & Cellular Proteomics 2024, 23: 100870. PMID: 39461475, PMCID: PMC11621936, DOI: 10.1016/j.mcpro.2024.100870.Peer-Reviewed Original ResearchDNA-damaging drugsTotal lymphocyte countCell linesResistance to DNA damaging drugsPD-L1Adjuvant chemotherapyProtein dynamicsProtein-level regulationSurvival benefitCopy number lossExpression time courseGastric cancerRelapse-free survival rateGastric cancer cellsHost immunityAssociated with prolonged survivalIncreased STAT1 phosphorylationResistance to other drugsGlobal protein dynamicsImmune checkpoint blockadePD-L1 positivityPD-L1 expressionAdvanced gastric cancerExpression of STAT1Molecular targeted drugsFinal Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma
Barata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason G, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Lerner S, Balzer-Haas N, Pal S. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal Of Clinical Oncology 2024, 42: 3911-3916. PMID: 39255440, PMCID: PMC11575905, DOI: 10.1200/jco.24.00767.Peer-Reviewed Original ResearchAdvanced papillary renal cell carcinomaPapillary renal cell carcinomaRenal cell carcinomaOverall survivalCell carcinomaProlonged progression-free survivalLack of survival benefitProgression-free survivalRandomized phase IIMedian Follow-UpPrimary end pointOpen-label trialOverall survival analysisCrizotinib armMedian OSSurvival benefitClinical trial updateNo significant differenceCabozantinibTreatment armsSunitinibFollow-upClinical trialsSavolitinibCrizotinibReal‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia
Rojek A, McCormick B, Cwykiel J, Odetola O, Abaza Y, Nai N, Foucar C, Achar R, Shallis R, Bradshaw D, Standridge M, Kota V, Murthy S, Badar T, Patel A. Real‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia. EJHaem 2024, 5: 728-737. PMID: 39157611, PMCID: PMC11327707, DOI: 10.1002/jha2.981.Peer-Reviewed Original ResearchPatients treated with ICEvent-free survivalTreated with ICCore binding factor acute myeloid leukemiaGemtuzumab ozogamicinIntensive chemotherapyCBF-AMLAcute myeloid leukemiaKIT inhibitorsOverall survivalEuropean LeukemiaNetMyeloid leukemiaThree-year overall survivalMedian Follow-UpInduction treatment regimensAntibody-drug conjugatesStatistically significant differenceImproved OSFavorable riskSurvival benefitTreatment regimensProspective studyFollow-upCompare outcomesAcademic centersTumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic L, Gebauer B, Jaffe A, Duncan J, Madoff D, Chapiro J. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making. European Radiology 2024, 35: 73-83. PMID: 39033181, DOI: 10.1007/s00330-024-10955-6.Peer-Reviewed Original ResearchMedian overall survivalTumor response criteriaTumor response assessmentHepatocellular carcinoma patientsHepatocellular carcinomaTumor responseOverall survivalResponse criteriaResponse assessmentNon-respondersPoorer median overall survivalPrediction of tumor responsePredictive valueHepatocellular Carcinoma ImmunotherapyDisease controlPrognostic of survivalClinical baseline parametersLog-rank testKaplan-Meier curvesMultivariate Cox regressionPredicting Overall SurvivalCox regression modelsSurvival benefitStratify patientsMRI pre-Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study
Vitale A, Trapani S, Russo F, Miele L, Baroni G, Marchesini G, Burra P, Ottoveggio M, Romagnoli R, Martini S, De Simone P, Carrai P, Cescon M, Morelli M, De Carlis L, Belli L, Gruttadauria S, Volpes R, Colledan M, Fagiuoli S, Di Benedetto F, De Maria N, Rossi G, Caccamo L, Donato F, Vennarecci G, Di Costanzo G, Vivarelli M, Carraro A, Sacerdoti D, Ettorre G, Giannelli V, Agnes S, Gasbarrini A, Rossi M, Corradini S, Mazzaferro V, Bhoori S, Manzia T, Lenci I, Zamboni F, Mameli L, Baccarani U, Toniutto P, Lupo L, Tandoi F, Rendina M, Andorno E, Giannini E, Spada M, Billato I, Marchini A, Romano P, Brancaccio G, D’Amico F, Ricci A, Cardillo M, Cillo U, del Fegato . A, . S, Trapianti C. Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study. JHEP Reports 2024, 6: 101147. PMID: 39282226, PMCID: PMC11399673, DOI: 10.1016/j.jhepr.2024.101147.Peer-Reviewed Original ResearchSurvival benefit of patientsTransplant survival benefitHepatocellular carcinomaLiver transplantationLiver diseaseIncreased waitlist mortalityPatient survivalBenefit of patientsSteatotic liver diseaseEnd-stage chronic liver diseaseAbstractText Label="Background &Waiting listImprove patient survivalWaitlist mortalityLiver transplant indicationsChronic liver diseaseAlcoholic liver diseaseRisk of deathWaiting list mortalityAbstractText Label="ImpactPrognostic featuresTransplant eligibility criteriaSurvival benefitTransplant indicationAdult patientsThe survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
Johnson K, Ni A, Quiroga D, Pariser A, Sudheendra P, Williams N, Sardesai S, Cherian M, Stover D, Gatti-Mays M, Ramaswamy B, Lustberg M, Jhawar S, Skoracki R, Wesolowski R. The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer. Npj Breast Cancer 2024, 10: 49. PMID: 38898072, PMCID: PMC11187074, DOI: 10.1038/s41523-024-00652-4.Peer-Reviewed Original ResearchInvasive disease-free survivalHER2+ breast cancerAdjuvant trastuzumabOverall survivalLocoregional therapyUnivariate analysisBreast cancerBenefit of adjuvant trastuzumabBenefits of adjuvant systemic therapyMulti-institutional retrospective analysisAdjuvant systemic therapyCompare survival outcomesDisease-free survivalTrastuzumab monotherapyNode-negativeSystemic therapyCombination therapySurvival benefitStatistically significant improvementSurvival outcomesRetrospective analysisMultivariate analysisPrimary outcomeTrastuzumabTherapyLongitudinal Assessment of Left Atrial Remodeling in Patients With Chronic Severe Aortic Regurgitation
Akintoye E, El Dahdah J, Dabbagh M, Patel H, Badwan O, Braghieri L, Chedid El Helou M, Kassab J, Jellis C, Desai M, Rodriguez L, Grimm R, Roselli E, Griffin B, Popovic Z. Longitudinal Assessment of Left Atrial Remodeling in Patients With Chronic Severe Aortic Regurgitation. JACC Cardiovascular Imaging 2024, 17: 1133-1145. PMID: 38878040, DOI: 10.1016/j.jcmg.2024.04.007.Peer-Reviewed Original ResearchLeft atrial volume indexLeft atrial reservoir strainAortic regurgitationLV parametersAssociated with survival benefitMedian follow-up periodChronic severe aortic regurgitationLeft ventricular (LVShort-term follow-upOptimal discriminatory thresholdsSevere aortic regurgitationAtrial volume indexIncremental prognostic valueAtrial reservoir strainLeft atrial remodelingFollow-up periodAssociated with survivalPredicting adverse eventsReservoir strainSerial echocardiographySevere ARSurvival benefitLA remodelingLV remodelingPrognostic valueAssociation between activating GNAS mutations and outcomes with chemotherapy in metastatic appendiceal adenocarcinoma.
Gujarathi R, Rodman C, Bansal V, Belmont E, Setia N, Alpert L, Hart J, Moller M, Eng O, Lee G, Chin J, Amin M, Polite B, Liao C, Turaga K, Shergill A. Association between activating GNAS mutations and outcomes with chemotherapy in metastatic appendiceal adenocarcinoma. Journal Of Clinical Oncology 2024, 42: 4179-4179. DOI: 10.1200/jco.2024.42.16_suppl.4179.Peer-Reviewed Original ResearchAppendiceal adenocarcinomaGNAS mutationsOverall survivalActivating GNAS mutationsGNAS statusSynchronous metastasesPredictive biomarkersMetastatic disease treated with chemotherapyCox proportional hazards regression analysisGNAS activating mutationsMetastatic appendiceal adenocarcinomaProportional hazards regression analysisEvent free survivalEvent-free survivalMedian Follow-UpHazards regression analysisFree survivalRadiographic recurrenceFavorable diseaseAA patientsSurvival benefitAssociated with differential outcomesClinicopathological characteristicsClinicopathological featuresNo significant differenceCurrent management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey.
Odzer N, Pusztai L, Rozenblit M. Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey. Journal Of Clinical Oncology 2024, 42: 1104-1104. DOI: 10.1200/jco.2024.42.16_suppl.1104.Peer-Reviewed Original ResearchMultimodal therapySurgical resectionOverall survivalPrimary tumorRandomized trialsResponse to initial chemotherapyTreated with multimodality therapyOligometastatic breast cancerRecommended surgical resectionLocally advanced cancerPalliative systemic chemotherapyProlonged overall survivalTime of diagnosisRandomized clinical trialsOS benefitSystemic chemotherapyInitial chemotherapyResidual lesionsSurvival benefitNCCN guidelinesReceptor subtypesRetrospective studyTreatment modalitiesMetastatic cancerAblative radiation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply